InvestorsHub Logo
Followers 1
Posts 91
Boards Moderated 0
Alias Born 06/14/2019

Re: None

Wednesday, 03/27/2024 7:12:17 PM

Wednesday, March 27, 2024 7:12:17 PM

Post# of 64728
Interesting! Skipping P2!! Amazing…

https://www.fiercebiotech.com/biotech/roche-places-stronger-gates-phase-3-pipeline-reduce-failure-rate

“The CEO blamed part of this downturn in late-stage clinical success rates on Tecentriq, where there had been a “push to go directly into phase 3, skipping phase 2, in order to catch up.” Tecentriq is one of many immune checkpoint inhibitors that got caught up in a PD-1/L1 land grab as Merck & Co.'s Keytruda rose to prominence.”

How are they “skipping Phase 2” at all? Well now…because they can. And so can TSOI.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TSOI News